Ocugen (MEX:OCGN) Current Deferred Revenue: MXN72.76 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:OCGN Ocugen Inc MEX:OCGN
37 GF Score
Price MXN25.00
GF Value MXN14.95
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocugen Current Deferred Revenue?

Ocugen MEX:OCGN 37 Current Deferred Revenue is MXN72.76 Mil as of Jun. 2026. GuruFocus rates MEX:OCGN with a GF Score™ of 37/100 and a GF Value™ of MXN14.95 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Ocugen's current deferred revenue for the quarter that ended in Jun. 2026 was MXN72.76 Mil.

Ocugen Current Deferred Revenue Related Terms

Ocugen Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Ocugen's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocugen Current Deferred Revenue Chart

Ocugen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 218.77 178.65 174.52 106.36

Ocugen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.33 104.27 106.36 93.93 72.76
MEX:OCGN
37GF Score
Ocugen Inc MEX:OCGN
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of MXN72.76 Mil mean?
Ocugen (MEX:OCGN) has a Current Deferred Revenue of MXN72.76 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ocugen and its competitors.
Is Ocugen's Current Deferred Revenue too high?
Ocugen's current Current Deferred Revenue is MXN72.76 Mil. Overall, Ocugen has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocugen's Current Deferred Revenue compare to EVMN and PBYI?
Ocugen's Current Deferred Revenue of MXN72.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ocugen and its competitors. Ocugen's current Current Deferred Revenue is MXN72.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocugen stock overvalued right now?
Based on GuruFocus' analysis, Ocugen (MEX:OCGN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN14.95, compared to a current price of MXN25.00 — trading 67.2% above its estimated fair value. The current Current Deferred Revenue is MXN72.76 Mil. Ocugen's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Ocugen (MEX:OCGN), the current Current Deferred Revenue is MXN72.76 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocugen (MEX:OCGN) Overvalued in 2026?

Based on GuruFocus' analysis, Ocugen stock appears to be overvalued. The current stock price of MXN25.00 is trading 67.2% above its estimated GF Value™ of MXN14.95. GuruFocus considers Ocugen to be Significantly Overvalued.

Key valuation signals for MEX:OCGN:

  • Current Deferred Revenue: MXN72.76 Mil
  • GF Value™: MXN14.95 vs. price of MXN25.00 (67.2% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the MEX:OCGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocugen Business Description

Other Exchanges OCGN:USA2H51:Germany
Address 11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
37GF Score

Get the complete analysis for MEX:OCGN

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN25.00
Price
MXN14.95
GF Value